# Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

> **NCT04991103** · PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma
- Amyloidosis

## Interventions

- **DRUG:** DaraVRD/DaraVCD

## Key facts

- **NCT ID:** NCT04991103
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-22
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-08-27
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991103, "Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04991103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*